Phase 3 Haemophilia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must have previously received the experimental gene therapy treatment (either giroctocogene fitelparvovec or fidanacogene eleparvovec) as part of a specific Pfizer-sponsored clinical study (one of the following studies: C0371002, C0371003, C0371005, C3731001, or C3731003).
Who may not be able to join:
- There are no specific exclusion criteria listed for this trial (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pfizer CT.gov Call Center, Pfizer
Phone: 1-800-718-1021
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
2 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Incidence of thromboembolic events; Incidence of factor inhibitor development; Incidence of hepatic malignancy; Incidence of liver abnormalities; Factor activity level
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.